Trial Profile
A Phase 3, Long-term Study in Patients With Chronic Kidney Disease (CKD) and Hyperphosphatemia on Hemodialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bixalomer (Primary)
- Indications Hyperphosphataemia; Renal failure
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 22 Dec 2014 New trial record